
Andrew John Lees

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3581380/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 181-184.	1.9	9,027
2	AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY. Brain, 1991, 114, 2283-2301.	7.6	3,002
3	The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 745-752.	1.9	2,935
4	Parkinson's disease. Lancet, The, 2009, 373, 2055-2066.	13.7	1,835
5	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 2008, 14, 501-503.	30.7	1,595
6	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
7	What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42, 1142-1142.	1.1	1,139
8	The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 2002, 125, 861-870.	7.6	1,108
9	Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease. Journal of Neurochemistry, 1989, 52, 1830-1836.	3.9	1,054
10	Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 1994, 36, 348-355.	5.3	1,052
11	ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE METALS IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA. Brain, 1991, 114, 1953-1975.	7.6	948
12	A Clinicopathologic Study of 100 Cases of Parkinson's Disease. Archives of Neurology, 1993, 50, 140-148.	4.5	881
13	COGNITIVE DEFICITS IN THE EARLY STAGES OF PARKINSON'S DISEASE. Brain, 1983, 106, 257-270.	7.6	818
14	Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain, 2005, 128, 1247-1258.	7.6	743
15	Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology, 2001, 57, 1497-1499.	1.1	729
16	Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8â€Hydroxyguanine Levels in Substantia Nigra. Journal of Neurochemistry, 1997, 69, 1196-1203.	3.9	715
17	Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Movement Disorders, 2000, 15, 503-510.	3.9	650
18	Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurology, The, 2009, 8, 270-279.	10.2	642

#	Article	IF	CITATIONS
19	Differing patterns of striatal18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Annals of Neurology, 1990, 28, 547-555.	5.3	641
20	Metaâ€analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
21	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	13.7	527
22	Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 423-428.	1.9	514
23	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	21.4	502
24	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain, 2011, 134, 1493-1505.	7.6	497
25	The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain, 2004, 127, 2657-2671.	7.6	493
26	INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN. Lancet, The, 1987, 330, 1219-1220	. 13.7	488
27	Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Movement Disorders, 2004, 19, 397-405.	3.9	488
28	A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease. Journal of Neurochemistry, 1997, 69, 1326-1329.	3.9	483
29	Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 388-396.	1.9	465
30	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology, 2006, 59, 852-858.	5.3	435
31	Parkin disease: a phenotypic study of a large case series. Brain, 2003, 126, 1279-1292.	7.6	427
32	Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Annals of Neurology, 1992, 32, 749-757.	5.3	426
33	Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with11C-raclopride and positron emission tomography. Annals of Neurology, 1992, 31, 184-192.	5.3	423
34	Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain, 2010, 133, 2045-2057.	7.6	414
35	What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Movement Disorders, 2010, 25, 2493-2500.	3.9	405
36	The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain, 2004, 127, 420-430.	7.6	404

#	Article	IF	CITATIONS
37	Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology, 2000, 54, 697-697.	1.1	401
38	Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Movement Disorders, 1994, 9, 92-97.	3.9	400
39	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology, 2001, 56, 1702-1706.	1.1	392
40	A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, The, 2005, 365, 415-416.	13.7	391
41	A clinico-pathological study of subtypes in Parkinson's disease. Brain, 2009, 132, 2947-2957.	7.6	385
42	The Nighttime Problems of Parkinson's Disease. Clinical Neuropharmacology, 1988, 11, 512-519.	0.7	382
43	α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathologica, 2013, 125, 753-769.	7.7	369
44	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.1	369
45	Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain, 2007, 130, 1566-1576.	7.6	364
46	The role of pathogenic <i>DJâ€I </i> mutations in Parkinson's disease. Annals of Neurology, 2003, 54, 283-286.	5.3	362
47	Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain, 2008, 131, 1362-1372.	7.6	355
48	Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain, 2010, 133, 1755-1762.	7.6	349
49	Parkinson's Disease Society Brain Bank, London: overview and research. Journal of Neural Transmission Supplementum, 1993, 39, 165-72.	0.5	347
50	Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nature Genetics, 2006, 38, 1032-1037.	21.4	344
51	A comparison of clinical and pathological features of young―and oldâ€onset Parkinson's disease. Neurology, 1988, 38, 1402-1402.	1.1	340
52	Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Annals of Neurology, 1994, 35, 38-44.	5.3	333
53	Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Movement Disorders, 2004, 19, 630-640.	3.9	332
54	Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species. Journal of Neurochemistry, 1998, 71, 2112-2122.	3.9	326

#	Article	IF	CITATIONS
55	Visual dysfunction in Parkinson's disease. Brain, 2016, 139, 2827-2843.	7.6	320
56	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128, 2786-2796.	7.6	315
57	Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ: British Medical Journal, 1995, 311, 1602-1607.	2.3	312
58	Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Molecular Brain Research, 1995, 28, 311-318.	2.3	304
59	Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain, 2004, 127, 21-33.	7.6	300
60	The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive) Tj ETQq0 0 0 rgBT	Qverlock	₹ 10 Tf 50 542 298
61	Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurology, The, 2005, 4, 605-610.	10.2	294
62	PINK1 protein in normal human brain and Parkinson's disease. Brain, 2006, 129, 1720-1731.	7.6	291
63	STRIATONIGRAL DEGENERATION. Brain, 1990, 113, 1823-1842.	7.6	289
64	Clutathione-related enzymes in brain in Parkinson's disease. Annals of Neurology, 1994, 36, 356-361.	5.3	287
65	Earlyâ€onset Lâ€dopaâ€responsive parkinsonism with pyramidal signs due to <i>ATP13A2, PLA2G6, FBXO7</i> and <i>spatacsin</i> mutations. Movement Disorders, 2010, 25, 1791-1800.	3.9	287
66	Subcutaneous apomorphine in the treatment of Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 96-101.	1.9	285
67	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain, 2011, 134, 969-978.	7.6	283
68	THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE. Neuropathology and Applied Neurobiology, 1989, 15, 27-44.	3.2	279
69	SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS. Lancet, The, 1988, 331, 403-406.	13.7	278
70	Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. Lancet Neurology, The, 2003, 2, 595-604.	10.2	278
71	Tremor in Parkinson's disease and serotonergic dysfunction. Neurology, 2003, 60, 601-605.	1.1	277
72	ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASE. Brain, 1984, 107, 487-506.	7.6	276

#	Article	IF	CITATIONS
73	Anti–basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology, 2002, 59, 227-231.	1.1	276
74	Deprenyl is metabolized to methamphetamine and amphetamine in man British Journal of Clinical Pharmacology, 1978, 6, 542-544.	2.4	270
75	DEPRENYL IN PARKINSON'S DISEASE. Lancet, The, 1977, 310, 791-795.	13.7	264
76	Clinical features and natural history of progressive supranuclear palsy. Neurology, 2003, 60, 910-916.	1.1	264
77	Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using singleâ€dose challenges. Movement Disorders, 2005, 20, 151-157.	3.9	262
78	The Psychopathology of the Gilles de la Tourette Syndrome. British Journal of Psychiatry, 1988, 152, 383-390.	2.8	257
79	Intense oxidative DNA damage promoted byl-DOPA and its metabolites implications for neurodegenerative disease. FEBS Letters, 1994, 353, 246-250.	2.8	249
80	Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?. Psychopharmacology, 1978, 57, 33-38.	3.1	247
81	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Movement Disorders, 2007, 22, 1757-1763.	3.9	246
82	Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, 71, 474-480.	1.1	246
83	Decreased Ferritin Levels in Brain in Parkinson's Disease. Journal of Neurochemistry, 1990, 55, 16-20.	3.9	244
84	CLINICAL AND PATHOLOGICAL FEATURES OF DIFFUSE CORTICAL LEWY BODY DISEASE (LEWY BODY) Tj ETQq 0 (0 0 rgBT /0 7.9	Overlock 10 T
85	Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 79-88.	1.9	241
86	Clinical usefulness of magnetic resonance imaging in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 65-71.	1.9	236
87	Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology, 2005, 65, 1570-1574.	1.1	233
88	Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study. Movement Disorders, 2008, 23, 101-106.	3.9	228
89	BRADYPHRENIA IN PARKINSON'S DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSIVE ILLNESS. Brain, 1987, 110, 761-776.	7.6	226
90	The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.	7.6	226

Brain, 2001, 124, 1438-1449.

#	Article	IF	CITATIONS
91	Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. Journal of Medical Genetics, 2005, 42, 837-846.	3.2	225
92	Natural history and syndromic associations of orthostatic tremor: A review of 41 patients. Movement Disorders, 2004, 19, 788-795.	3.9	224
93	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. Movement Disorders, 2010, 25, 560-569.	3.9	223
94	Maladaptive plasticity of serotonin axon terminals in levodopaâ€induced dyskinesia. Annals of Neurology, 2010, 68, 619-628.	5.3	221
95	Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years. Movement Disorders, 1993, 8, 165-170.	3.9	220
96	Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 2009, 16, 1148-1152.	1.5	220
97	Dopamine dysregulation syndrome in Parkinson's disease. Current Opinion in Neurology, 2004, 17, 393-398.	3.6	218
98	The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathology and Applied Neurobiology, 2012, 38, 4-24.	3.2	218
99	Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy. Movement Disorders, 2007, 22, 2235-2241.	3.9	216
100	Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Movement Disorders, 2002, 17, 1235-1241.	3.9	210
101	Role of DATâ€SPECT in the diagnostic work up of Parkinsonism. Movement Disorders, 2007, 22, 1229-1238.	3.9	206
102	The clinical features and natural history of the Steeleâ€Richardsonâ€Olszewski syndrome (progressive) Tj ETQqC	00rgBT	/Overlock 10 206
103	The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Human Molecular Genetics, 2005, 14, 2399-2404.	2.9	205
104	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurology, 2019, 76, 470.	9.0	205
105	Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 573-576.	1.9	204
106	Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Annals of Neurology, 2003, 54, 235-238.	5.3	204
107	Dopamine Dysregulation Syndrome. CNS Drugs, 2009, 23, 157-170.	5.9	203
108	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics, 2011, 20, 345-353.	2.9	202

#	Article	IF	CITATIONS
109	Neurological deterioration in young adults with phenylketonuria. Lancet, The, 1990, 336, 602-605.	13.7	201
110	Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1672-1677.	1.9	201
111	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
112	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathologica, 2017, 133, 337-352.	7.7	193
113	Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain, 2006, 129, 1040-1049.	7.6	192
114	Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain, 2012, 135, 1141-1153.	7.6	191
115	Accuracy of clinical diagnosis of progressive supranuclear palsy. Movement Disorders, 2004, 19, 181-189.	3.9	190
116	Pathophysiological differences between musician's dystonia and writer's cramp. Brain, 2005, 128, 918-931.	7.6	190
117	Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiology of Aging, 2012, 33, 814-823.	3.1	184
118	The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology, 1997, 49, 1570-1576.	1.1	183
119	Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 72-76.	1.9	182
120	Kufor Rakeb Disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Movement Disorders, 2005, 20, 1264-1271.	3.9	177
121	Lewy body cortical involvement may not always predict dementia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 852-856.	1.9	176
122	Self-injurious behaviour and the Gilles de la Tourette syndrome: a clinical study and review of the literature. Psychological Medicine, 1989, 19, 611-625.	4.5	173
123	Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. Neurology, 2006, 67, 1612-1617.	1.1	173
124	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1073-1083.	1.7	173
125	The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain, 2005, 128, 1855-1860.	7.6	172
126	Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain, 2007, 130, 2123-2128.	7.6	172

#	Article	IF	CITATIONS
127	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain, 2013, 136, 400-411.	7.6	172
128	Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain, 2010, 133, 727-745.	7.6	171
129	Some Specific Clinical Features Differentiate Multiple System Atrophy (Striatonigral Variety) From Parkinson's Disease. Archives of Neurology, 1995, 52, 294-298.	4.5	170
130	Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology, 2005, 64, 675-679.	1.1	168
131	Botulinum toxin treatment in spasmodic torticollis Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 640-643.	1.9	165
132	ENCEPHALITIS LETHARGICA. Brain, 1987, 110, 19-33.	7.6	164
133	Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet, The, 1990, 336, 32-34.	13.7	164
134	Multiple system atrophy–parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2012, 27, 1186-1190.	3.9	164
135	<i>ATP13A2</i> mutations (PARK9) cause neurodegeneration with brain iron accumulation. Movement Disorders, 2010, 25, 979-984.	3.9	163
136	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2012, 27, 1754-1762.	3.9	163
137	Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 317-321.	1.9	162
138	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	9.0	162
139	Remission in spasmodic torticollis Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 1236-1237.	1.9	159
140	In vivo studies on striatal dopamine D ₁ and D ₂ site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology, 1997, 49, 717-723.	1.1	159
141	Intact Reward Learning but Elevated Delay Discounting in Parkinson's Disease Patients With Impulsive-Compulsive Spectrum Behaviors. Neuropsychopharmacology, 2010, 35, 2155-2164.	5.4	159
142	Dystonia in parkinson's disease: Clinical and pharmacological features. Annals of Neurology, 1988, 23, 73-78.	5.3	158
143	Donepezil in Parkinson's disease dementia: A randomized, doubleâ€blind efficacy and safety study. Movement Disorders, 2012, 27, 1230-1238.	3.9	158
144	Anal Sphincter Dysfunction in Parkinson's Disease. Archives of Neurology, 1989, 46, 1061-1064.	4.5	156

#	Article	IF	CITATIONS
145	A clinical study of Gilles de la Tourette syndrome in the United Kingdom Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 1-8.	1.9	154
146	α-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18666-18671.	7.1	154
147	The midbrain to pons ratio. Neurology, 2013, 80, 1856-1861.	1.1	153
148	The dopaminergic response in multiple system atrophy Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1009-1013.	1.9	152
149	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Medicine, 2017, 14, e1002314.	8.4	152
150	Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 602-607.	1.9	150
151	Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain, 1997, 120, 75-90.	7.6	149
152	Alphaâ€synuclein mRNA expression in oligodendrocytes in MSA. Glia, 2014, 62, 964-970.	4.9	149
153	Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. Brain, 2004, 128, 116-125.	7.6	148
154	Lowâ€dose Lâ€dopa therapy in Parkinson's disease. Neurology, 1986, 36, 1528-1528.	1.1	147
155	Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. Journal of Neurochemistry, 2006, 98, 156-169.	3.9	146
156	Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson's disease patients. Acta Neuropathologica, 2008, 115, 417-425.	7.7	146
157	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 197.	9.0	146
158	Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 468-473.	1.9	145
159	Ten-year follow-up of three different initial treatments in de-novo PD. Neurology, 2001, 57, 1687-1694.	1.1	141
160	Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain, 2002, 125, 2248-2256.	7.6	141
161	Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon?. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1503-1507.	1.9	140
162	Dopaminergic function in familial Parkinson's disease: A clinical and ¹⁸ Fâ€dopa positron emission tomography study. Annals of Neurology, 1997, 41, 222-229.	5.3	140

#	Article	IF	CITATIONS
163	Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 850-854.	1.9	137
164	Olfaction and Parkinson's syndromes: its role in differential diagnosis. Current Opinion in Neurology, 2004, 17, 417-423.	3.6	137
165	OBSESSIONAL SLOWNESS. Brain, 1991, 114, 2191-2202.	7.6	135
166	The nature of apraxia in corticobasal degeneration Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 455-459.	1.9	134
167	STEELE-RICHARDSON-OLSZEWSKI SYNDROME. Brain, 1988, 111, 615-630.	7.6	133
168	The Effect of Sleep on the Dyskinetic Movements of Parkinson's Disease, Gilles de la Tourette Syndrome, Huntington's Disease, and Torsion Dystonia. Archives of Neurology, 1991, 48, 210-214.	4.5	133
169	Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single <i>parkin</i> mutation. Neurology, 2005, 64, 134-136.	1.1	132
170	Diffusionâ€weighted magnetic resonance imaging differentiates Parkinsonian variant of multipleâ€system atrophy from progressive supranuclear palsy. Movement Disorders, 2007, 22, 68-74.	3.9	132
171	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	7.6	132
172	Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1981, 44, 1020-1023.	1.9	130
173	Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology, 2004, 62, 1224-1226.	1.1	127
174	THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. Movement Disorders, 2012, 27, 1290-1294.	3.9	126
175	UCHL-1is not a Parkinson's disease susceptibility gene. Annals of Neurology, 2006, 59, 627-633.	5.3	123
176	The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. Movement Disorders, 2008, 23, 2328-2334.	3.9	122
177	The prediagnostic phase of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 871-878.	1.9	122
178	Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?. Neurology, 2002, 59, 1486-1491.	1.1	121
179	The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders, 2013, 28, 232-236.	3.9	121
180	Brain iron deposition is linked with cognitive severity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 418-425.	1.9	121

#	Article	IF	CITATIONS
181	A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain, 1998, 121, 59-75.	7.6	120
182	Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. Brain, 1993, 116, 281-302.	7.6	119
183	Regional brain volumes distinguish PSP, MSAâ€P, and PD: MRIâ€based clinicoâ€radiological correlations. Movement Disorders, 2006, 21, 989-996.	3.9	119
184	Parkin Disease. JAMA Neurology, 2013, 70, 571.	9.0	119
185	Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model. Movement Disorders, 2010, 25, 2508-2515.	3.9	117
186	Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain, 2011, 134, 2339-2357.	7.6	116
187	The pre-morbid personality of patients with Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 97-100.	1.9	115
188	THE AUDITORY STARTLE RESPONSE IN THE STEELE-RICHARDSON-OLSZEWSKI SYNDROME AND PARKINSON'S DISEASE. Brain, 1992, 115, 1181-1192.	7.6	115
189	ROLE OF SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN VOIDING DYSFUNCTION. Lancet, The, 1988, 332, 1451-1453.	13.7	114
190	Diaphragmatic flutter, the moving umbilicus syndrome, and ?belly dancer's? dyskinesia. Movement Disorders, 1990, 5, 15-22.	3.9	114
191	The Genetic and Pathological Classification of Familial Frontotemporal Dementia. Archives of Neurology, 2001, 58, 1813.	4.5	114
192	Bone health in Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1159-1166.	1.9	114
193	Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundamental and Clinical Pharmacology, 1993, 7, 121-128.	1.9	113
194	Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 1995, 66, 361-376.	2.3	112
195	Tau gene and Parkinson's disease: a case-control study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 962-965.	1.9	112
196	Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1749-1752.	1.9	111
197	Alteration in α-synuclein mRNA expression in Parkinson's disease. Movement Disorders, 2004, 19, 162-170.	3.9	111
198	Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology, 1991, 41, 1723-1723.	1.1	110

#	Article	IF	CITATIONS
199	Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neuroscience Letters, 2009, 453, 77-80.	2.1	110
200	Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Molecular Brain Research, 1998, 63, 62-71.	2.3	107
201	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	3.9	106
202	What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsyâ€parkinsonism (PSPâ€P)?. Movement Disorders, 2010, 25, 357-362.	3.9	106
203	Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 277-286.	2.8	106
204	Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 718-723.	1.9	104
205	Unusual focal dyskinesias: The ears, the shoulders, the back, and the abdomen. Movement Disorders, 1994, 9, 531-538.	3.9	104
206	Treatment of dystonic clenched fist with botulinum toxin. Movement Disorders, 2001, 16, 907-913.	3.9	104
207	Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain, 2004, 127, 1332-1342.	7.6	104
208	Ropinirole in the Treatment of Levodopa-Induced Motor Fluctuations in Patients with Parkinson's Disease. Clinical Neuropharmacology, 1996, 19, 234-245.	0.7	103
209	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 665-667.	1.9	103
210	Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Annals of Neurology, 2012, 71, 850-854.	5.3	103
211	Dopa-responsive dystonia: [18F]dopa positron emission tomography. Annals of Neurology, 1991, 30, 24-30.	5.3	100
212	Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. Movement Disorders, 1995, 10, 179-187.	3.9	100
213	[¹²³ I] FP IT spect study in vascular parkinsonism and Parkinson's disease. Movement Disorders, 2007, 22, 1278-1285.	3.9	100
214	A validation exercise on the new consensus criteria for multiple system atrophy. Movement Disorders, 2009, 24, 2272-2276.	3.9	100
215	Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1234-1239.	1.9	98
216	Writer's cramp: Treatment with botulinum toxin injections. Movement Disorders, 1991, 6, 55-59.	3.9	98

#	Article	IF	CITATIONS
217	Familial progressive supranuclear palsy. Brain, 1995, 118, 1095-1103.	7.6	98
218	Validation of the MDSâ€UPDRS Part I for nonmotor symptoms in Parkinson's disease. Movement Disorders, 2012, 27, 79-83.	3.9	97
219	PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 688-692.	1.9	96
220	Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease. Neurochemistry International, 2003, 43, 129-135.	3.8	96
221	Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 228-234.	1.9	95
222	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
223	Comparison of motor response to apomorphine and levodopa in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 1004-1007.	1.9	92
224	When did Ray Kennedy's Parkinson's disease begin?. Movement Disorders, 1992, 7, 110-116.	3.9	92
225	Auctioneer's jaw: A case of occupational oromandibular hemidystonia. Movement Disorders, 1995, 10, 508-509.	3.9	92
226	Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations. Brain, 2001, 124, 331-340.	7.6	92
227	The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 193-200.	1.9	91
228	Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 652-655.	1.9	91
229	Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1223-1228.	1.9	91
230	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	1.9	90
231	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
232	Neuronal inclusions of Parkinson's disease. Movement Disorders, 1991, 6, 2-11.	3.9	88
233	Proton magnetic resonance spectroscopy in steele-richardson-olszewski syndrome. Movement Disorders, 1997, 12, 767-771.	3.9	88
234	A Randomized Controlled Pilot Study to Evaluate a Technology Platform for the Assisted Living of People with Dementia and their Carers. Journal of Alzheimer's Disease, 2014, 41, 515-523.	2.6	88

#	Article	IF	CITATIONS
235	CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?. Journal of Neuroimmunology, 2003, 136, 149-153.	2.3	87
236	Abnormalities of the blink reflex in Gilles de la Tourette syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 895-898.	1.9	86
237	Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ: British Medical Journal, 1998, 316, 1191-1196.	2.3	86
238	Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology, 2003, 61, 102-104.	1.1	86
239	Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions?. Movement Disorders, 2012, 27, 1137-1145.	3.9	85
240	Spinal internuncial neurones in progressive encephalomyelitis with rigidity Journal of Neurology, Neurosurgery and Psychiatry, 1979, 42, 773-785.	1.9	84
241	Management of Gilles de la Tourette Syndrome Using Sulpiride. Clinical Neuropharmacology, 1990, 13, 229-235.	0.7	84
242	Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 624-629.	1.9	84
243	[123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. Annals of Neurology, 2003, 53, 489-496.	5.3	83
244	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1065-1075.	1.9	83
245	The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. Neurodegenerative Diseases, 2014, 13, 154-156.	1.4	83
246	Multiple system atrophy/progressive supranuclear palsy: α-Synuclein, synphilin, tau, and <i>APOE</i> . Neurology, 2000, 55, 1918-1920.	1.1	82
247	Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain, 2001, 124, 769-783.	7.6	82
248	Hyposmia in G2019S LRRK2-related parkinsonism. Neurology, 2008, 71, 1021-1026.	1.1	82
249	Pathological report of four patients presenting with cranial dystonias. Movement Disorders, 1988, 3, 211-221.	3.9	81
250	High resolution MR anatomy of the subthalamic nucleus: Imaging at 9.4T with histological validation. NeuroImage, 2012, 59, 2035-2044.	4.2	81
251	Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 186-189.	1.9	80
252	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain, 2002, 125, 969-975.	7.6	80

Andrew John Lees

#	Article	IF	CITATIONS
253	Effects of Treatment on Airway Dynamics and Respiratory Muscle Strength in Parkinson's Disease. The American Review of Respiratory Disease, 1993, 148, 1576-1580.	2.9	79
254	Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 634-637.	1.9	78
255	Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. Journal of Neurochemistry, 2003, 86, 394-404.	3.9	78
256	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
257	Recent observations on the clinical pharmacology of (-)deprenyl. Journal of Neural Transmission, 1978, 43, 245-251.	2.8	76
258	The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit onâ€off fluctuations British Journal of Clinical Pharmacology, 1986, 22, 429-436.	2.4	76
259	Punding and dyskinesias. Movement Disorders, 2006, 21, 2214-2217.	3.9	76
260	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain, 2011, 134, 2548-2564.	7.6	76
261	Four pioneers of Lâ€dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders, 2015, 30, 19-36.	3.9	76
262	The clinical phenomenon of akathisia Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 861-866.	1.9	75
263	The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred. Annals of Neurology, 1992, 32, 609-617.	5.3	75
264	Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome. Brain, 1995, 118, 951-958.	7.6	75
265	Movement disorders in 30 patients with tuberculous meningitis. Movement Disorders, 2000, 15, 561-569.	3.9	75
266	Diffuse lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report. Movement Disorders, 1992, 7, 355-358.	3.9	73
267	?-tocopherol levels in brain are not altered in Parkinson's disease. Annals of Neurology, 1992, 32, 591-593.	5.3	73
268	Marijuana for parkinsonian tremor Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 436-436.	1.9	72
269	Low-dose olanzapine for levodopa induced dyskinesias. Neurology, 2000, 55, 795-799.	1.1	72
270	Sensorimotor reorganization by proprioceptive training in musician's dystonia and writer's cramp. Neurology, 2008, 70, 304-315.	1.1	72

#	Article	IF	CITATIONS
271	Diffuse Lewy body disease presenting with a supranuclear gaze palsy Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 159-161.	1.9	71
272	The treatment of Gilles de la Tourette syndrome by limbic leucotomy Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 691-694.	1.9	70
273	Can stress trigger Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 878-881.	1.9	70
274	Buspirone in the treatment of levodopa induced dyskinesias Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 376-377.	1.9	69
275	The Slow Axonal Transport of the Microtubule-Associated Protein Tau and the Transport Rates of Different Isoforms and Mutants in Cultured Neurons. Journal of Neuroscience, 2002, 22, 6394-6400.	3.6	69
276	Dopamine transporter binding in Gilles de la Tourette syndrome: a [1231]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica, 2004, 109, 140-146.	4.5	69
277	Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and <scp>P</scp> arkinson's Disease. Brain Pathology, 2013, 23, 263-273.	4.1	69
278	Healthâ€related quality of life in patients with progressive supranuclear palsy. Movement Disorders, 2003, 18, 1464-1469.	3.9	68
279	Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase, 2005, 11, 274-282.	0.6	68
280	Neuropathological findings in benign tremulous Parkinsonism. Movement Disorders, 2013, 28, 145-152.	3.9	68
281	Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathologica, 2011, 122, 415-428.	7.7	67
282	Novelty seeking behaviour in Parkinson's disease. Neuropsychologia, 2011, 49, 2483-2488.	1.6	66
283	An ambulatory dyskinesia monitor. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 196-201.	1.9	65
284	Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. Neurology, 2004, 63, 638-643.	1.1	65
285	Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 744-748.	1.9	65
286	A pathological study of the association between Lewy body disease and Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 701-708.	1.9	64
287	Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Movement Disorders, 2005, 20, 1425-1430.	3.9	64
288	Development and assessment of sensitive immunoâ€ <scp>PCR</scp> assays for the quantification of cerebrospinal fluid three―and fourâ€repeat tau isoforms in tauopathies. Journal of Neurochemistry, 2012, 123, 396-405.	3.9	64

#	Article	IF	CITATIONS
289	Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin. Journal of Neurology, 1992, 239, 1-4.	3.6	63
290	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Movement Disorders, 2010, 25, 896-905.	3.9	63
291	Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Current Treatment Options in Neurology, 2016, 18, 42.	1.8	63
292	BACKWARD WALKING AND CIRCLING: BEHAVIOURAL RESPONSES INDUCED BY DRUG TREATMENTS WHICH CAUSE SIMULTANEOUS RELEASE OF CATECHOLAMINES AND 5â€HYDROXYTRYPTAMINE. British Journal of Pharmacology, 1979, 66, 573-579.	5.4	62
293	Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Movement Disorders, 2000, 15, 336-337.	3.9	62
294	Diagnostic considerations in juvenile parkinsonism. Movement Disorders, 2004, 19, 123-135.	3.9	62
295	Off-period belching due to a reversible disturbance of oesophageal motility in Parkinso's disease and its treatment with apomorphine. Movement Disorders, 1989, 4, 47-52.	3.9	61
296	Acute movement disorders with bilateral basal ganglia lesions in uremia. Movement Disorders, 1998, 13, 952-957.	3.9	61
297	Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Movement Disorders, 2006, 21, 1737-1741.	3.9	61
298	The Parkinson chimera. Neurology, 2009, 72, S2-11.	1.1	61
299	Patterns of EMG-EMG coherence in limb dystonia. Movement Disorders, 2004, 19, 758-769.	3.9	60
300	Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings. Movement Disorders, 2003, 18, 28-33.	3.9	59
301	A functional polymorphism regulating dopamine ?-hydroxylase influences against Parkinson's disease. Annals of Neurology, 2004, 55, 443-446.	5.3	59
302	Does levodopa accelerate the pathologic process in Parkinson disease brain?. Neurology, 2011, 77, 1420-1426.	1.1	59
303	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	3.9	59
304	Parkinson's disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
305	Paroxysmal dystonic head tremor. Movement Disorders, 1991, 6, 85-86.	3.9	58
306	A new look at James Parkinson's <i>Essay on the Shaking Palsy</i> . Neurology, 2007, 69, 482-485.	1.1	58

#	Article	IF	CITATIONS
307	Transportin1: a marker of FTLD-FUS. Acta Neuropathologica, 2011, 122, 591-600.	7.7	58
308	Serotonergic involvement in behavioural responses to amphetamine at high dosage. Neuropharmacology, 1979, 18, 153-158.	4.1	57
309	Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 577-580.	1.9	57
310	Adult-onset tic disorders. Movement Disorders, 2002, 17, 735-740.	3.9	56
311	The black stuff and Konstantin Nikolaevich Tretiakoff. Movement Disorders, 2008, 23, 777-783.	3.9	55
312	The clinical features of pathologically confirmed vascular Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1027-1029.	1.9	55
313	Problems in the Diagnosis of Progressive Supranuclear Palsy (Steele — Richardson — Olszewski) Tj ETQq1 1 0	784314 r 0.5	gBT_/Overloc
314	Selegiline-induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal. Movement Disorders, 1999, 14, 246-251.	3.9	54
315	Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. Brain, 2004, 127, 2441-2451.	7.6	54
316	Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. Journal of Neurology, 2013, 260, 1009-1013.	3.6	54
317	Treatment of Motor Fluctuations in Parkinson's Disease with an Oral Sustained-Release Preparation of L-Dopa. Clinical Neuropharmacology, 1986, 9, 430-439.	0.7	53
318	Late Progression of Post-Encephalitic Parkinson's Syndrome. Canadian Journal of Neurological Sciences, 1988, 15, 135-138.	0.5	53
319	Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 442-446.	1.9	53
320	A geographical cluster of progressive supranuclear palsy in northern France. Neurology, 2015, 85, 1293-1300.	1.1	53
321	Bromocriptine in Parkinsonism. Archives of Neurology, 1978, 35, 503.	4.5	52
322	Complex stereotypies after right putaminal infarction: A case report. Movement Disorders, 1991, 6, 358-361.	3.9	52
323	The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Letters, 2002, 531, 538-542.	2.8	52
324	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. PLoS ONE, 2014, 9, e96260.	2.5	52

#	Article	IF	CITATIONS
325	The contribution of amphetamine metabolites of (?)-deprenyl to its antiparkinsonian properties. Journal of Neural Transmission, 1982, 54, 105-110.	2.8	51
326	Magnetic resonance spectroscopic study of parkinsonism related to boxing Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 688-691.	1.9	51
327	Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction. Neurology, 2020, 94, e1525-e1538.	1.1	51
328	Analysis of <i>tau</i> haplotypes in Pick's disease. Neurology, 2002, 59, 443-445.	1.1	50
329	J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology, 2008, 70, 566-573.	1.1	50
330	Excessive hoarding in Parkinson's disease. Movement Disorders, 2010, 25, 1026-1033.	3.9	50
331	Giant cell arteritis with spinal cord infarction and basilar artery thrombosis Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 945-948.	1.9	49
332	The effects of oral protein on the absorption of intraduodenal levodopa and motor performance Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1063-1067.	1.9	49
333	Subcortical neurofibrillary degeneration presenting as steeleâ€richardsonâ€olszewski and other related syndromes: A review of 90 pathologically verified cases. Movement Disorders, 1994, 9, 381-389.	3.9	49
334	Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neuroscience Letters, 2001, 311, 145-148.	2.1	49
335	New therapeutic indications for botulinum toxins. Movement Disorders, 2004, 19, S157-S161.	3.9	49
336	Holmes tremor: Application of modern neuroimaging techniques. Movement Disorders, 2006, 21, 2260-2262.	3.9	49
337	Hyposmia in pure autonomic failure. Neurology, 2009, 72, 1677-1681.	1.1	49
338	9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease. NeuroImage: Clinical, 2017, 13, 154-163.	2.7	49
339	Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain, 2000, 123, 1422-1430.	7.6	48
340	High dose naltrexone for dyskinesias induced by levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 554-556.	1.9	48
341	Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease. Neurobiology of Aging, 2009, 30, 1477-1482.	3.1	48
342	Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward. Movement Disorders, 2010, 25, 867-876.	3.9	48

#	Article	IF	CITATIONS
343	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. Npj Parkinson's Disease, 2018, 4, 2.	5.3	47
344	Intranasal apomorphine in Parkinson's disease. Neurology, 1991, 41, 761-762.	1.1	46
345	Neuronal intranuclear inclusion disease and juvenile Parkinsonism. Movement Disorders, 2000, 15, 990-995.	3.9	46
346	Neuronal intranuclear inclusion disease: Report on a case originally diagnosed as dopa-responsive dystonia with Lewy bodies. Movement Disorders, 2005, 20, 1345-1349.	3.9	46
347	New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology, 1991, 41, 820-820.	1.1	46
348	Amyloid ?-peptide and the dementia of Parkinson's diease. Movement Disorders, 1996, 11, 647-653.	3.9	45
349	Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Movement Disorders, 2005, 20, 1115-1119.	3.9	45
350	The Â-synuclein gene in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 464-467.	1.9	45
351	MRI derived brain atrophy in PSP and MSA-P. Journal of Neurology, 2007, 254, 478-481.	3.6	45
352	Minimal change multiple system atrophy: An aggressive variant?. Movement Disorders, 2015, 30, 960-967.	3.9	45
353	NEUROSYPHILIS TODAY. Lancet, The, 1979, 313, 90-93.	13.7	44
354	Genome-Wide Analysis of the Parkinsonism-Dementia Complex of Guam. Archives of Neurology, 2004, 61, 1889-97.	4.5	44
355	Nigrostriatal dysfunction in homozygous and heterozygous <i>parkin</i> gene carriers: An ¹⁸ Fâ€dopa PET progression study. Movement Disorders, 2009, 24, 2260-2266.	3.9	44
356	LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Neuropathology and Applied Neurobiology, 2011, 37, 777-790.	3.2	44
357	Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease. Brain, 2021, 144, 1787-1798.	7.6	44
358	Mutation in thetau exon 10 splice site region in familial frontotemporal dementia. Annals of Neurology, 1999, 45, 270-271.	5.3	43
359	Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Experimental Neurology, 2006, 199, 465-478.	4.1	43
360	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	3.9	43

#	Article	IF	CITATIONS
361	Pantothenate kinaseâ€essociated neurodegeneration is not a synucleinopathy. Neuropathology and Applied Neurobiology, 2013, 39, 121-131.	3.2	43
362	The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager) Tj ETQq0	0 0 rgBT /Ov	erlock 10 Tf 50

363	Familial Progressive supranuclear Palsy. Archives of Neurology, 2001, 58, 1846.	4.5	42
364	Normal dopamine transporter single photonâ€emission CT scan in corticobasal degeneration. Movement Disorders, 2008, 23, 2424-2426.	3.9	42
365	Neuropathology of primary adult-onset dystonia. Neurology, 2008, 70, 695-699.	1.1	42
366	Differential DJ-1 gene expression in Parkinson's disease. Neurobiology of Disease, 2009, 36, 393-400.	4.4	42
367	Applying a new version of the Brazilian-Portuguese UPSIT smell test in Brazil. Arquivos De Neuro-Psiquiatria, 2010, 68, 700-705.	0.8	42
368	Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 183-188.	0.6	42
369	Baclofen in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1978, 41, 707-708.	1.9	41
370	Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1024-1026.	1.9	41
371	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathologica, 2006, 112, 439-449.	7.7	41
372	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. Journal of Neurology, 2015, 262, 2653-2661.	3.6	41
373	Single versus multiple impulse control disorders in Parkinson's disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. Journal of Neurology, 2015, 262, 1504-1514.	3.6	41
374	Neurofibrillary tangle parkinsonian disorders?tau pathology andtau genetics. Movement Disorders, 1999, 14, 731-736.	3.9	40
375	Spinocerebellar ataxia type 17: Extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. Movement Disorders, 2005, 20, 1521-1523.	3.9	40
376	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiology of Disease, 2005, 20, 401-411.	4.4	40
377	Quantifying the impact of dyskinesias in PD. Neurology, 2007, 69, 555-563.	1.1	40
378	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Molecular Genetics and Metabolism, 2011, 103, 410-412.	1.1	40

#	Article	IF	CITATIONS
379	Pathological gambling in Parkinson's disease—a review of the literature. Movement Disorders, 2011, 26, 1976-1984.	3.9	40
380	Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: Evidence from Parkinson's disease Behavioral Neuroscience, 2013, 127, 245-255.	1.2	40
381	Pisa syndrome in Parkinson's disease: a mobile or fixed deformity?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1400-1403.	1.9	40
382	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. Parkinsonism and Related Disorders, 2016, 27, 35-40.	2.2	40
383	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology, 2018, 90, e1849-e1857.	1.1	40
384	Niacin Depletion in Parkinsonian Patients Treated with L-dopa, Benserazide and Carbidopa. Clinical Science, 1979, 56, 89-93.	4.3	39
385	Rectal apomorphine in Parkinson's disease. Lancet, The, 1991, 337, 118.	13.7	39
386	Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 601-607.	1.9	39
387	A clinical and pathological study of motor neurone disease on Guam. Brain, 2001, 124, 2215-2222.	7.6	39
388	Attention and cognition in bradykinetic-rigid syndromes: An event-related potential study. Annals of Neurology, 2001, 50, 567-573.	5.3	39
389	SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology, 2001, 56, 266-267.	1.1	39
390	The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neuroscience Letters, 2002, 330, 201-203.	2.1	39
391	Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies. Movement Disorders, 2004, 19, 1190-1196.	3.9	39
392	Clinical features of childhoodâ€onset paroxysmal kinesigenic dyskinesia with <scp><i>PRRT</i></scp> <i>2</i> gene mutations. Developmental Medicine and Child Neurology, 2013, 55, 327-334.	2.1	39
393	Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 139-144.	2.8	39
394	The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. Neurobiology of Aging, 2015, 36, 1221.e1-1221.e6.	3.1	39
395	The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset. Neuroscience Letters, 1986, 65, 79-83.	2.1	38
396	The gene responsible forPARK6 Parkinson's disease,PINK1, does not influence common forms of parkinsonism. Annals of Neurology, 2004, 56, 329-335.	5.3	38

#	Article	IF	CITATIONS
397	Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka. Movement Disorders, 2009, 24, 1229-1233.	3.9	38
398	The effect of drug treatment on neurogenesis in Parkinson's disease. Movement Disorders, 2011, 26, 45-50.	3.9	38
399	Neuropathological features of multiple system atrophy with cognitive impairment. Movement Disorders, 2014, 29, 884-888.	3.9	38
400	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
401	Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 430-434.	1.9	37
402	Cerebellar axial postural tremor. Movement Disorders, 1997, 12, 977-984.	3.9	37
403	Parkinson's syndrome after closed head injury: a single case report. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 380-385.	1.9	37
404	Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 944-948.	1.9	37
405	Variation at the <i>TRIM11</i> locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
406	The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's Disease. Journal of Clinical Psychopharmacology, 1995, 15, 51S-59S.	1.4	37
407	The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathologica, 1987, 73, 195-201.	7.7	36
408	A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1224-1227.	1.9	36
409	The relationship between eye-winking tics, frequent eye-blinking and blepharospasm Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 477-480.	1.9	36
410	Parkinsonism associated with acute intracranial hematomas: An [18F]dopa positron-emission tomography study. Movement Disorders, 1997, 12, 1035-1038.	3.9	36
411	Anti-basal ganglia antibodies in patients with atypical dystonia and tics. Neurology, 2004, 63, 156-158.	1.1	36
412	Sporadic rapid-onset dystonia-parkinsonism presenting as Parkinson's disease. Movement Disorders, 2006, 21, 118-119.	3.9	36
413	Characterisation of a novel NR4A2 mutation in Parkinson's disease brain. Neuroscience Letters, 2009, 457, 75-79.	2.1	36
414	Sublingual apomorphine and Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1440-1440.	1.9	35

#	Article	IF	CITATIONS
415	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgraduate Medical Journal, 1999, 75, 579-584.	1.8	35
416	Quality of life in patients with orthostatic tremor. Journal of Neurology, 2003, 250, 212-215.	3.6	35
417	Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments. Journal of Parkinson's Disease, 2013, 3, 231-239.	2.8	35
418	HALLUCINATIONS AFTER WITHDRAWAL OF BACLOFEN. Lancet, The, 1977, 309, 858.	13.7	34
419	Kinesigenic foot dystonia as a presenting feature of Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 885-885.	1.9	34
420	A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid decarboxylase antibodies [corrected]. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 449-451.	1.9	34
421	The motor response to sequential apomorphine in parkinsonian fluctuations Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 358-360.	1.9	34
422	Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neuroscience Letters, 1997, 221, 161-164.	2.1	34
423	Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism–dementia complex and Guadeloupean parkinsonism. Parkinsonism and Related Disorders, 2002, 9, 39-54.	2.2	34
424	Upregulation of dopamine D ₂ receptors in dopaminergic drugâ€naive patients with <i>parkin</i> gene mutations. Movement Disorders, 2006, 21, 783-788.	3.9	34
425	The corticotrophinâ€releasing factorâ€like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. European Journal of Neuroscience, 2007, 26, 417-423.	2.6	34
426	The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. Movement Disorders, 2009, 24, 1144-1153.	3.9	34
427	Putaminal Upregulation of FosB/î"FosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia. Journal of Parkinson's Disease, 2011, 1, 347-357.	2.8	34
428	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34
429	Dopaminergic function in patients with posttraumatic parkinsonism: An ¹⁸ F-dopa PET study. Neurology, 1997, 49, 183-189.	1.1	33
430	[¹²³ I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia. Neurology, 2002, 59, 1974-1976.	1.1	33
431	How do patients with parkinsonism present? A clinicopathological study. Internal Medicine Journal, 2009, 39, 7-12.	0.8	33
432	Impulsiveâ€compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Movement Disorders, 2010, 25, 638-642.	3.9	33

#	Article	IF	CITATIONS
433	Olfactory heterogeneity in <i>LRRK2</i> related Parkinsonism. Movement Disorders, 2010, 25, 2879-2883.	3.9	33
434	Difference in MSA Phenotype Distribution between Populations: Genetics or Environment?. Journal of Parkinson's Disease, 2012, 2, 7-18.	2.8	33
435	Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy. Neurobiology of Aging, 2014, 35, 1514.e1-1514.e12.	3.1	33
436	Parkin maintains mitochondrial levels of the protective Parkinson's disease-related enzyme 17-β hydroxysteroid dehydrogenase type 10. Cell Death and Differentiation, 2015, 22, 1563-1576.	11.2	33
437	A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps. Movement Disorders Clinical Practice, 2017, 4, 323-328.	1.5	33
438	HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 180-185.	1.9	32
439	Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. Movement Disorders, 2005, 20, 479-484.	3.9	32
440	Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology, 2007, 68, 1553-1554.	1.1	32
441	ls transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. Movement Disorders, 2012, 27, 1182-1185.	3.9	32
442	Nocturnal and respiratory disturbances in Steele-Richardson-Olszewski syndrome (progressive) Tj ETQq0 0 0 rgB	Г /Qyerloc 1.8	k 10 Tf 50 38
443	Torticollis due to disinhibition of the vestibulo-collic reflex in a patient with Steele-Richardson-Olszewski syndrome. Movement Disorders, 1997, 12, 328-336.	3.9	31
444	GPi Firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine. Movement Disorders, 1999, 14, 481-483.	3.9	31
445	Botulinum toxin A as treatment for drooling saliva in PD. Neurology, 2000, 55, 606-607.	1.1	31
446	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. Movement Disorders, 2016, 31, 668-675.	3.9	31
447	Phenotypes, genotypes, and the management of paroxysmal movement disorders. Developmental Medicine and Child Neurology, 2018, 60, 559-565.	2.1	31
448	Apomorphine in the treatment of Parkinson's disease: a review. Arquivos De Neuro-Psiquiatria, 2018, 76, 840-848.	0.8	31
449	Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease. Brain, 2020, 143, 3435-3448.	7.6	31
450	Hippocampal α-synuclein pathology correlates with memory impairment in multiple system atrophy. Brain, 2020, 143, 1798-1810.	7.6	31

#	Article	IF	CITATIONS
451	The metabolic effects of limbic leucotomy in Gilles de la Tourette syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1016-1019.	1.9	30
452	Botulinum Toxin in the Treatment of Writer's Cramp. Clinical Neuropharmacology, 1996, 19, 314-320.	0.7	30
453	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathologica, 2009, 118, 359-369.	7.7	30
454	Nitric oxide synthase mRNA expression in human subthalamic nucleus, striatum and globus pallidus: implications for basal ganglia function. Molecular Brain Research, 1994, 22, 329-332.	2.3	29
455	Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis. Movement Disorders, 2005, 20, S114-S118.	3.9	29
456	NONCOMPRESSIVE MYELOPATHY ASSOCIATED WITH VIOLENT AXIAL TICS OF TOURETTE SYNDROME. Neurology, 2010, 74, 697-698.	1.1	29
457	Olfactory impairment in familial ataxias. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 970-974.	1.9	29
458	Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series. Parkinson's Disease, 2013, 2013, 1-5.	1.1	29
459	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	1.9	29
460	Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 511-517.	1.9	28
461	Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration. Acta Neuropathologica, 2006, 112, 633-645.	7.7	28
462	Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease. Neuropathology and Applied Neurobiology, 2008, 34, 492-505.	3.2	28
463	Tiapride in levodopa-induced involuntary movements Journal of Neurology, Neurosurgery and Psychiatry, 1979, 42, 380-383.	1.9	27
464	Strong association of the <i>Saitohin</i> gene Q7 variant with progressive supranuclear palsy. Neurology, 2003, 61, 407-409.	1.1	27
465	Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 620-622.	1.9	27
466	The motor prodromes of parkinson's disease: from bedside observation to large-scale application. Journal of Neurology, 2021, 268, 2099-2108.	3.6	27
467	Selegiline hydrochloride and cognition. Acta Neurologica Scandinavica, 1991, 84, 91-94.	2.1	26
468	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	2.1	26

#	Article	IF	CITATIONS
469	Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. Movement Disorders, 2003, 18, 1123-1131.	3.9	26
470	Safety and Efficacy of Tolcapone in the Long-term Use in Parkinson Disease. Clinical Neuropharmacology, 2014, 37, 1-5.	0.7	26
471	Late onset ataxia: MSA or SCA 17? A gene penetrance dilemma. Movement Disorders, 2014, 29, 36-38.	3.9	26
472	The Pharmacology of Foot Dystonia in Parkinsonism. Clinical Neuropharmacology, 1987, 10, 47-56.	0.7	25
473	Apomorphine in the Diagnosis and Treatment of Parkinsonian Tremor. Clinical Neuropharmacology, 1990, 13, 312-317.	0.7	25
474	Incidental Lewy body disease in black Africans. Lancet, The, 1994, 344, 882-883.	13.7	25
475	Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Movement Disorders, 2007, 22, 895-897.	3.9	25
476	The auditory startle response in parkinsonism may reveal the extent but not type of pathology. Journal of Neurology, 2008, 255, 628-632.	3.6	25
477	In vivo assessment of brain monoamine systems in parkin gene carriers: A PET study. Experimental Neurology, 2010, 222, 120-124.	4.1	25
478	Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 883-887.	1.9	25
479	Increased reflection impulsivity in patients with ephedroneâ€induced <scp>P</scp> arkinsonism. Addiction, 2013, 108, 771-779.	3.3	25
480	Dopamine reuptake transporter–singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
481	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. JAMA Neurology, 2022, 79, 359.	9.0	25
482	The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Movement Disorders, 1989, 4, 53-74.	3.9	24
483	Sublingual Apomorphine in the Treatment of Parkinson's Disease Complicated by Motor Fluctuations. Clinical Neuropharmacology, 1991, 14, 556-561.	0.7	24
484	Drugs for Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 607-610.	1.9	24
485	Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. Movement Disorders, 2007, 22, 1594-1600.	3.9	24
486	Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease. CNS Neuroscience & Therapeutics, 2008, 14, 83-93.	4.0	24

#	Article	IF	CITATIONS
487	Severe dysphagia as a presentation of Parkinson's disease. Movement Disorders, 2012, 27, 457-458.	3.9	24
488	Shell shock at Queen Square: Lewis Yealland 100 years on. Brain, 2013, 136, 1976-1988.	7.6	24
489	The spectrum of involuntary vocalizations in humans: A video atlas. Movement Disorders, 2019, 34, 1774-1791.	3.9	24
490	Telemedicine in Movement Disorders: Leçons du COVIDâ€19. Movement Disorders, 2020, 35, 1893-1896.	3.9	24
491	Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. Brain, 2021, 144, 1138-1151.	7.6	24
492	The Motor Response to Repeated Apomorphine Administration in Parkinson's Disease. Clinical Neuropharmacology, 1991, 14, 209-213.	0.7	23
493	L-dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. Movement Disorders, 2004, 19, 1232-1236.	3.9	23
494	Can olfactory bulb biopsy be justified for the diagnosis of Parkinson's disease? Comments on "olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders― Acta Neuropathologica, 2009, 117, 213-214.	7.7	23
495	Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies. Journal of Neuroscience Methods, 2009, 180, 34-42.	2.5	23
496	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. Movement Disorders Clinical Practice, 2019, 6, 462-469.	1.5	23
497	Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 555-561.	1.9	23
498	Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease. Acta Neurologica Scandinavica, 1983, 68, 113-116.	2.1	22
499	Diurnal differences in response to oral levodopa Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 948-950.	1.9	22
500	Micrographia associated with a parietal lobe lesion in multiple sclerosis Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 739-741.	1.9	22
501	Levodopa Substitution: The Gold Standard. Clinical Neuropharmacology, 1994, 17, S1-S6.	0.7	22
502	Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 1996, 75, 389-406.	2.3	22
503	Use of apomorphine in Parkinson's disease. British Journal of Hospital Medicine, 1999, 60, 816-820.	0.2	22
504	Use of smell test identification in Parkinson's disease in Mexico: A matched case ontrol study. Movement Disorders, 2011, 26, 173-176.	3.9	22

#	Article	IF	CITATIONS
505	MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy. Journal of Neurology, 2013, 260, 1031-1036.	3.6	22
506	Perceptual decision-making in patients with Parkinson's disease. Journal of Psychopharmacology, 2014, 28, 1149-1154.	4.0	22
507	Georges Gilles de la Tourette. The man and his times. Revue Neurologique, 1986, 142, 808-16.	1.5	22
508	Torticollis after electrocution. Movement Disorders, 1993, 8, 117-118.	3.9	21
509	Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome. Movement Disorders, 1999, 14, 530-532.	3.9	21
510	Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study. Movement Disorders, 2003, 18, 694-697.	3.9	21
511	Parkinson's disease with Onuf's nucleus involvement mimicking multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 232-234.	1.9	21
512	DYT16: the original cases: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1012-1014.	1.9	21
513	Progressive Parkinsonism, Balance Difficulties, and Supranuclear Gaze Palsy. JAMA Neurology, 2014, 71, 104.	9.0	21
514	Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. Acta Neuropathologica Communications, 2014, 2, 24.	5.2	21
515	PERGOLIDE AND LISURIDE FOR LEVODOPA-INDUCED OSCILLATIONS. Lancet, The, 1981, 318, 577.	13.7	20
516	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Molecular Brain Research, 2004, 121, 95-101.	2.3	20
517	A genetic cluster of early onset Parkinson's disease in a Colombian population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 885-889.	1.7	20
518	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
519	Differential antagonism by neuroleptics of backward-walking and other behaviours caused by amphetamine at high dosage. Neuropharmacology, 1980, 19, 549-553.	4.1	19
520	Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 972-975.	1.9	19
521	Botulinum toxin BMJ: British Medical Journal, 1992, 305, 1169-1170.	2.3	19
522	Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1249-1251.	1.9	19

#	Article	IF	CITATIONS
523	A neuromyotonic process in a transposed latissimus dorsi muscle stemming from radiotherapy and peripheral surgery. Movement Disorders, 1996, 11, 449-451.	3.9	19
524	Sign language tics in a prelingually deaf man. Movement Disorders, 2000, 15, 318-320.	3.9	19
525	Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate?. Neuroscience Letters, 2009, 467, 208-211.	2.1	19
526	Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Movement Disorders, 2012, 27, 1323-1323.	3.9	19
527	<i>Banisteriopsis caapi</i> , a Forgotten Potential Therapy for Parkinson's Disease?. Movement Disorders Clinical Practice, 2016, 3, 19-26.	1.5	19
528	Jumping to conclusions in untreated patients with Parkinson's disease. Neuropsychologia, 2016, 85, 19-23.	1.6	19
529	Subtle motor disturbances in PREDICT-PD participants. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 212-217.	1.9	19
530	Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase, 2018, 24, 204-212.	0.6	19
531	Treatment of nonoccupational limb and trunk dystonia with botulinum toxin. Movement Disorders, 1996, 11, 377-383.	3.9	18
532	Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 120-123.	1.7	18
533	Parkinson's disease: A broken nosology. Movement Disorders, 2005, 20, S2-S4.	3.9	18
534	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic andparkin-linked Parkinson's disease. Movement Disorders, 2006, 21, 299-305.	3.9	18
535	Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. Neuropsychologia, 2011, 49, 103-107.	1.6	18
536	Chorea in digoxin toxicity Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 419-419.	1.9	17
537	New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta Neurologica Scandinavica, 1989, 80, 139-145.	2.1	17
538	Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 388-390.	1.9	17
539	EMG-EMG coherence in writer's cramp. Movement Disorders, 2002, 17, 1011-1016.	3.9	17
540	UCHL-1 gene in multiple system atrophy: A haplotype tagging approach. Movement Disorders, 2005, 20, 1338-1343.	3.9	17

#	Article	IF	CITATIONS
541	The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 954-955.	1.9	17
542	Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. Brain, 2019, 142, 3580-3591.	7.6	17
543	Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 169-179.	1.9	17
544	Persistent rheumatic chorea. Neurology, 1985, 35, 101-101.	1.1	17
545	HEMIDYSTONIA RELIEVED BY NICOTINE. Lancet, The, 1984, 324, 871.	13.7	16
546	Nonparkinsonian Tremors. Clinical Neuropharmacology, 2000, 23, 233-238.	0.7	16
547	Bilaterally coherent tremor resembling enhanced physiological tremor: Report of three cases. Movement Disorders, 2002, 17, 387-391.	3.9	16
548	The Neuro-Behavioural Syndrome of Brainstem Disease. Neurocase, 2008, 13, 452-465.	0.6	16
549	Reckless generosity in Parkinson's disease. Movement Disorders, 2010, 25, 221-223.	3.9	16
550	Effects of Age and Cognition on a Cross-Cultural Paediatric Adaptation of the Sniffin' Sticks Identification Test. PLoS ONE, 2015, 10, e0131641.	2.5	16
551	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
552	Parkinsonism due to Kernohan notch: Clinical, structural, and functional imaging correlates. Neurology, 2004, 62, 2333-2334.	1.1	15
553	Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Movement Disorders, 2004, 19, 1006-1011.	3.9	15
554	Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1594-1596.	1.9	15
555	NR4A2 genetic variation in sporadic Parkinson's disease: A genewide approach. Movement Disorders, 2006, 21, 1960-1963.	3.9	15
556	Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor–Ataxia syndrome. Movement Disorders, 2009, 24, 1245-1247.	3.9	15
557	An essay on the shaking palsy. Brain, 2017, 140, 843-848.	7.6	15
558	Endocrine aspects of bromocriptine therapy in Parkinsonism. Journal of Neural Transmission, 1978, 43, 153-160.	2.8	14

#	Article	IF	CITATIONS
559	Prevalence of lewy bodies in alzheimer's disease. Annals of Neurology, 1989, 26, 691-692.	5.3	14
560	Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 413-413.	1.9	14
561	Hallucinations and parkinsonian Motor Fluctuations. Behavioural Neurology, 1992, 5, 83-86.	2.1	14
562	Pathological substrate for regional distribution of increased atrophy rates in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1772-1775.	1.9	14
563	Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 267-272.	1.9	14
564	The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study. Movement Disorders Clinical Practice, 2018, 5, 519-522.	1.5	14
565	Methysergide in progressive supranuclear palsy. Neurology, 1985, 35, 936-936.	1.1	14
566	Reversible coma in Wernicke's encephalopathy. Postgraduate Medical Journal, 1985, 61, 607-610.	1.8	13
567	PAROXYSMAL HEMIGLOSSAL TWISTING. Lancet, The, 1986, 328, 812-813.	13.7	13
568	A Double-Blind, Controlled Study of High-Dose L-Deprenyl in the Treatment of Parkinson's Disease. Clinical Neuropharmacology, 1989, 12, 448.	0.7	13
569	Down's syndrome and Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 289-289.	1.9	13
570	Melanized nigral neuronal numbers in Nigerian and British individuals. Movement Disorders, 2006, 21, 1239-1241.	3.9	13
571	Muscarinic Receptors in the Thalamus in Progressive Supranuclear Palsy and Other Neurodegenerative Disorders. Journal of Neuropathology and Experimental Neurology, 2007, 66, 399-404.	1.7	13
572	Olfaction in pathologically proven patients with multiple system atrophy. Movement Disorders, 2012, 27, 327-328.	3.9	13
573	Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinson's Disease Patients. Journal of Parkinson's Disease, 2019, 9, 625-630.	2.8	13
574	<i>MYORG</i> -related disease is associated with central pontine calcifications and atypical parkinsonism. Neurology: Genetics, 2020, 6, e399.	1.9	13
575	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. Npj Parkinson's Disease, 2021, 7, 33.	5.3	13
576	Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy-like syndrome. Movement Disorders, 2003, 18, 331-336.	3.9	12

#	Article	IF	CITATIONS
577	The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 571-575.	1.9	12
578	Olfactory function in Parkinson's disease in ON versus OFF states. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1293-1295.	1.9	12
579	An intragenic duplication in guanosine triphosphate cyclohydrolaseâ€1 gene in a dopaâ€responsive dystonia family. Movement Disorders, 2011, 26, 905-909.	3.9	12
580	The new Bradykinesia Akinesia Incoordination (BRAIN) test: Preliminary data from an online test of upper limb movement. Movement Disorders, 2012, 27, 157-158.	3.9	12
581	BROMOCRIPTINE IN TREATMENT OF LEVODOPA-INDUCED END-OF-DOSE DYSTONIA. Lancet, The, 1980, 316, 215-216.	13.7	11
582	Exaggerated startle reflexes in an elderly woman. Movement Disorders, 1990, 5, 167-169.	3.9	11
583	Letters to the Editor. Movement Disorders, 1992, 7, 387-391.	3.9	11
584	A case of progressive subcortical gliosis associated with deposition of abnormal prion protein (PrP). Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 759-760.	1.9	11
585	Yawning in Parkinson's disease. Neurology, 1999, 52, 428-428.	1.1	11
586	Development, characterisation and epitope mapping of novel monoclonal antibodies for DJ-1 (PARK7) protein. Neuroscience Letters, 2005, 383, 225-230.	2.1	11
587	A Huntington's disease phenocopy characterized by pallido-nigro-luysian degeneration with brain iron accumulation and p62-positive glial inclusions. Neuropathology and Applied Neurobiology, 2010, 36, 551-557.	3.2	11
588	A film of patients with movement disorders made in Queen Square, London in the Midâ€1920s by Samuel Alexander Kinnier Wilson. Movement Disorders, 2011, 26, 2453-2459.	3.9	11
589	MSA or SCA 17? A clinicopathological case update. Movement Disorders, 2016, 31, 1582-1584.	3.9	11
590	Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 633-641.	1.9	11
591	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. Expert Review of Neurotherapeutics, 2017, 17, 649-659.	2.8	11
592	The auditory startle response in progressive supranuclear palsy. Journal of Neural Transmission Supplementum, 1994, 42, 43-50.	0.5	11
593	GROWTH-HORMONE RESPONSE TO BROMOCRIPTINE IN PARKINSONISM. Lancet, The, 1976, 307, 194.	13.7	10
594	Bromocriptine in presenile dementia BMJ: British Medical Journal, 1978, 1, 1052-1053.	2.3	10

#	Article	IF	CITATIONS
595	Histocompatibility antigens and post-encephalitic Parkinsonism Journal of Neurology, Neurosurgery and Psychiatry, 1982, 45, 1060-1061.	1.9	10
596	Platelet phenolsulphotransferase activity in Parkinson's disease. Journal of Neural Transmission, 1983, 57, 95-102.	2.8	10
597	The Controversial Role of Bromocriptine in Parkinson's Disease. Clinical Neuropharmacology, 1985, 8, 150-155.	0.7	10
598	Cigarette smoking, Parkinson's disease and ulcerative colitis Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 635-635.	1.9	10
599	Selegiline and mortality in Parkinson's disease: Another view. Annals of Neurology, 1997, 41, 282-283.	5.3	10
600	Mortality in DATATOP. Annals of Neurology, 1999, 45, 138-139.	5.3	10
601	Polymyography Combined with Time-Locked Video Recording (Video EMC) for Presurgical Assessment of Patients with Cervical Dystonia. European Neurology, 2001, 45, 222-228.	1.4	10
602	Influence of target size on vertical gaze palsy in a pathologically proven case of progressive supranuclear palsy. Movement Disorders, 2003, 18, 818-822.	3.9	10
603	Hypoxic ischemia and proteasome dysfunction alter tau isoform ratio by inhibiting exon 10 splicing. Journal of Neurochemistry, 2010, 114, 160-170.	3.9	10
604	Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies. Movement Disorders, 2012, 27, 1615-1616.	3.9	10
605	Anterior tibial compartment syndrome following prolonged tetany. Journal of Neurology, Neurosurgery and Psychiatry, 1976, 39, 406-408.	1.9	9
606	Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report. Movement Disorders, 1991, 6, 342-346.	3.9	9
607	Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 373-373.	1.9	9
608	Ropinirole (SK and F 101468) in the treatment of Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 938-938.	1.9	9
609	The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 771-775.	1.9	9
610	Possible clinical overlap between postencephalitic parkinsonism and progressive supranuclear palsy Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 589-590.	1.9	9
611	Parkinsonism following electrical injury to the hand. Movement Disorders, 1998, 13, 600-602.	3.9	9
612	Long duration asymmetric postural tremor in the development of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 9-9.	1.9	9

#	Article	IF	CITATIONS
613	Unified Parkinson's Disease Rating Scale (UPDRS) part I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 586-587.	2.2	9
614	In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 579-583.	2.8	9
615	<scp>TDP</scp> â€43 pathology is present in most postâ€encephalitic parkinsonism brains. Neuropathology and Applied Neurobiology, 2014, 40, 654-657.	3.2	9
616	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.	2.2	9
617	Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. Clinical Neurology and Neurosurgery, 2016, 147, 71-77.	1.4	9
618	Reply to: "A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders― Movement Disorders, 2020, 35, 1903-1904.	3.9	9
619	Tendency to late recurrence following rheumatic chorea. Neurology, 1989, 39, 999-999.	1.1	9
620	Case of DYT1 dystonia triggered by bite from a moray. Movement Disorders, 2006, 21, 1536-1537.	3.9	8
621	Camptocormia: don't forget muscle disease in the movement disorder clinic. Journal of Neurology, 2012, 259, 1752-1754.	3.6	8
622	Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson's disease. Journal of Neurology, 2012, 259, 2419-2423.	3.6	8
623	The strange case of Dr William Gowers and Mr Sherlock Holmes. Brain, 2015, 138, 2103-2108.	7.6	8
624	Mesulergine and pergolide in previously untreated Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 482-484.	1.9	7
625	Hereditary juvenile parkinsonism with pyramidal signs and mental retardation. European Journal of Neurology, 1995, 2, 23-26.	3.3	7
626	Multiple sclerosis leading to blepharospasm and dystonia in a sibling pair. Journal of Neurology, 1996, 243, 667-670.	3.6	7
627	Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology, 1998, 50, 573.	1.1	7
628	How Can Neuroimaging Help in the Diagnosis of Movement Disorders?. Neuroimaging Clinics of North America, 2010, 20, 111-123.	1.0	7
629	William Gowers: the never completed third edition of the 'Bible of Neurology'. Brain, 2012, 135, 3178-3188.	7.6	7
630	Yorkshire's influence on the foundation of British Neurology. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 6-9.	1.9	7

#	Article	IF	CITATIONS
631	Oral r-(-)-11-o-valeryl-n- <i>n</i> -propylnoraporphine reverses motor deficits in mptp-treated marmosets. Movement Disorders, 2016, 31, 1381-1388.	3.9	7
632	Crime and Parkinson's: The jury is out. Movement Disorders, 2018, 33, 1092-1094.	3.9	7
633	James Parkinson's Chimera: syndrome or disease?. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 190-195.	0.6	7
634	Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: Contrast with other dementias. Journal of Chemical Neuroanatomy, 2008, 35, 268-274.	2.1	6
635	Neurology and detective writing. Practical Neurology, 2013, 13, 372-376.	1.1	6
636	Webâ€based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	3.9	6
637	The relationship between the First World War and neurology: 100 years of "Shell Shock― Arquivos De Neuro-Psiquiatria, 2017, 75, 317-319.	0.8	6
638	Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1121-1123.	1.9	6
639	Medical conferences: value for money?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 483-484.	1.9	6
640	Neuropathological Findings in Ephedrone Encephalopathy. Movement Disorders, 2020, 35, 1858-1863.	3.9	6
641	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. Journal of Parkinson's Disease, 2021, 11, 1901-1915.	2.8	6
642	Bird watching on the asphalt. Brain, 2021, 144, 2-5.	7.6	6
643	Autosomal recessive late onset multisystem disorder with cerebellar cortical atrophy at necropsy: report of a family Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 853-856.	1.9	5
644	Stuttering, tic-like facial movements and behavioural disorders. Journal of Neurology, 1995, 243, 105-106.	3.6	5
645	Reporting Clinical Trials: Full Access to All of the Data. Archives of Neurology, 2002, 59, 27.	4.5	5
646	Reporting clinical trials. Neurology, 2002, 58, 347-348.	1.1	5
647	Reporting clinical trials: Full access to all the data. Movement Disorders, 2002, 17, 3-4.	3.9	5
648	Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans. Neuroscience Letters, 2004, 359, 94-98.	2.1	5

#	Article	IF	CITATIONS
649	Clinical grand round: A rapidly progressive pyramidal and extrapyramidal syndrome with a supranuclear gaze palsy. Movement Disorders, 2005, 20, 826-831.	3.9	5
650	Konstantin N. Tretiakoff in Brazil a historical perspective and discussion of his contribution to brazilian neuroscience. Arquivos De Neuro-Psiquiatria, 2009, 67, 322-327.	0.8	5
651	Familial camptocormia: from dystonia to myopathy: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 350-351.	1.9	5
652	How reliable are prodromal indicators of Parkinson disease?. Nature Reviews Neurology, 2015, 11, 5-6.	10.1	5
653	Diagnosing social anxiety in Parkinson's disease: characteristics and frequencies according to two diagnostic criteria. Revista De Psiquiatria Clinica, 2016, 43, 139-142.	0.6	5
654	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
655	Visual hallucinations. Practical Neurology, 2021, 21, 327-332.	1.1	5
656	The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. Advances in Neurology, 1996, 69, 393-8.	0.8	5
657	Sustained levodopa therapy in tardive dyskinesia Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 685-685.	1.9	4
658	Case 2, 1991: Unusual tremor, myoclonus, and a limping gait. Movement Disorders, 1991, 6, 371-375.	3.9	4
659	Temporary deterioration in Parkinsonian signs after modest alcohol intake. Movement Disorders, 1992, 7, 284-285.	3.9	4
660	Inverse masticatory muscle activity due to syringobulbia. Movement Disorders, 1993, 8, 359-360.	3.9	4
661	Atypical parkinsonism in the French West Indies. Lancet, The, 1999, 354, 1474.	13.7	4
662	Lesion of the dorsorostral midbrain sparing the nigrostriatal tract mimics axial rigidity seen in progressive supranuclear palsy. Movement Disorders, 2005, 20, 1071-1075.	3.9	4
663	Did Gustav Mahler have Sydenham's chorea?. Movement Disorders, 2006, 21, 289-292.	3.9	4
664	Decades of delayed diagnosis in 4 levodopaâ€responsive youngâ€onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	3.9	4
665	Late Emergence of Parkinsonian Phenotype and Abnormal Dopamine Transporter Scan in Choreaâ€Acanthocytosis. Movement Disorders Clinical Practice, 2015, 2, 182-186.	1.5	4
666	Wilson's disease: the 60th anniversary of Walshe's article on treatment with penicillamine. Arquivos De Neuro-Psiquiatria, 2017, 75, 69-71.	0.8	4

#	Article	IF	CITATIONS
667	Neuropathological progression of clinical Parkinson disease subtypes. Nature Reviews Neurology, 2019, 15, 361-361.	10.1	4
668	Noticing in neurology. Practical Neurology, 2019, 19, 427-430.	1.1	4
669	Lewy body disease. Neurology, 1989, 39, 878.	1.1	4
670	Diagnosis of PD. Neurology, 1993, 43, 1630-1630.	1.1	4
671	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. Npj Parkinson's Disease, 2021, 7, 87.	5.3	4
672	Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegenerative Disease Management, 2022, 12, 77-91.	2.2	4
673	BROMOCRIPTINE AND THYROID-STIMULATING-HORMONE SECRETION. Lancet, The, 1977, 310, 1128-1129.	13.7	3
674	Tics. Behavioural Neurology, 1990, 3, 99-108.	2.1	3
675	Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets. Movement Disorders, 2007, 22, 715-719.	3.9	3
676	Up with the lark. Neurology, 2011, 77, 310-311.	1.1	3
677	Primary progressive aphasia with parkinsonism. Movement Disorders, 2013, 28, 741-746.	3.9	3
678	Hyposmia in SWEDD. Movement Disorders, 2015, 30, 1436-1437.	3.9	3
679	The Story of "Speed―from "Cloud Nine―to Brain Gain. International Review of Neurobiology, 2015, 120, 1-7.	2.0	3
680	Testing the reflexes. BMJ: British Medical Journal, 2019, 366, 14830.	2.3	3
681	The long-term outcome of impulsive compulsive behaviours in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
682	Patients' Postjudice of Teleâ€Neurology for Movement Disorders. Movement Disorders Clinical Practice, 2022, 9, 446-451.	1.5	3
683	Motor response to apomorphine and levodopa in asymmetric Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1444-1444.	1.9	2
684	Reply. Movement Disorders, 2000, 15, 587-588.	3.9	2

#	Article	IF	CITATIONS
685	Antiparkinsonian drugs and visual hallucinations – Authors' response. Lancet Neurology, The, 2006, 5, 19-20.	10.2	2
686	W R Gowers 1895: two unpublished post-graduate lectures. Brain, 2012, 135, 3165-3177.	7.6	2
687	The more cortical amyloidâ€Î², the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?. Movement Disorders, 2013, 28, 263-264.	3.9	2
688	William Burroughs: Sailor of the Soul. Journal of Psychoactive Drugs, 2017, 49, 385-392.	1.7	2
689	Parkinson's disease – 200 years: the outstanding contribution of "Old Hubert― Arquivos De Neuro-Psiquiatria, 2017, 75, 192-194.	0.8	2
690	Endemic atypical parkinsonism. Journal of the Neurological Sciences, 2018, 388, 220-221.	0.6	2
691	Listening with intent. Practical Neurology, 2019, 20, practneurol-2019-002307.	1.1	2
692	Lithium: a slow burner. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 335-337.	1.9	2
693	Expanding the links between Brazilian and British neurology. Arquivos De Neuro-Psiquiatria, 2010, 68, 493-494.	0.8	2
694	Neuropsychiatric Features of Punding and Hobbyism in Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 82-86.	1.5	2
695	MATTERS ARISING: Leiguarda et al reply:. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1549-1549.	1.9	1
696	POMD01 Blinded analysis of conventional MRI in a cohort of pathologically confirmed parkinsonian illnesses. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e57-e57.	1.9	1
697	Preface. Neuroimaging Clinics of North America, 2010, 20, xiii.	1.0	1
698	Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: Clinicopathological case. Movement Disorders, 2011, 26, 424-429.	3.9	1
699	PARKIN DISEASE–A CLINICOPATHOLOGICAL ENTITY?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.35-e2.	1.9	1
700	Availability of olfactory bulb: experience from a British Brain Bank. Arquivos De Neuro-Psiquiatria, 2013, 71, 110-112.	0.8	1
701	A Brazilian Football Player Still on the Pitch After 10ÂYears of Parkinson's Disease with Severe Freezing of Gait. Movement Disorders Clinical Practice, 2015, 2, 43-44.	1.5	1
702	Intrathoracic Malignancy Mimicking Axial Dystonia. Movement Disorders Clinical Practice, 2016, 3, 203-205.	1.5	1

#	Article	IF	CITATIONS
703	Hemichoreoâ€hemibalism as a Manifestation of Central Nervous System Chronic Graftâ€versusâ€Host Disease. Movement Disorders Clinical Practice, 2017, 4, 495-498.	1.5	1
704	Concerns Regarding Opicapone as Adjunct to Levodopa Therapy–Reply. JAMA Neurology, 2017, 74, 873.	9.0	1
705	Advice for those trying to find a cure for the shaking palsy. Lancet Neurology, The, 2018, 17, 27-28.	10.2	1
706	Face-making: task-specific facial tensions and grimacing in musicians. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1180-1182.	1.9	1
707	Tricks of the trade. Arquivos De Neuro-Psiquiatria, 2012, 70, 245-245.	0.8	1
708	Reply to â€~Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.'. Parkinsonism and Related Disorders, 2021, 93, 31-32.	2.2	1
709	REM Sleep Behavior Disorder and Visual Hallucinations in a Pathologically Confirmed Case of Corticobasal Degeneration. Movement Disorders Clinical Practice, 2022, 9, 383-385.	1.5	1
710	Alzheimer pathology in Parkinson's disease. Neurology, 1989, 39, 874.	1.1	1
711	Tics. Behavioural Neurology, 1990, 3, 99-108.	2.1	1
712	Levodopa induced chorea in Meige syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 286-286.	1.9	0
713	MATTERS ARISING: Davie et al reply:. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 562-562.	1.9	Ο
714	Unusual tremor associated with a posterolateral thalamic lesion in a drummer. Movement Disorders, 2001, 16, 174-176.	3.9	0
715	Reporting clinical trials: full access to all the data. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 143-143.	1.9	Ο
716	Reporting clinical trials: full access to all the data. Journal of Neurology, 2002, 249, 638-639.	3.6	0
717	Dopamine transporter imaging. Movement Disorders, 2003, 18, S1-S2.	3.9	0
718	Dementia in dementia with Lewy bodies may not be attributable to Alzheimer pathology. Annals of Neurology, 2004, 56, 604-604.	5.3	0
719	P4-035 Melanized nigral neurons in Caucasians and Africans. Neurobiology of Aging, 2004, 25, S482.	3.1	0
720	Reply: Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study. Movement Disorders, 2005, 20, 1086-1087.	3.9	0

#	Article	IF	CITATIONS
721	POC08 A case of central and peripheral vestibular vestibular failure. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e36-e37.	1.9	0
722	PATH54 Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e22-e22.	1.9	0
723	0854â€Camptocormia: what is the cause?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.159-e1.	1.9	0
724	120â€An algorithm to identify individuals at high-risk of Parkinson's disease in the community. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.71-e1.	1.9	0
725	118â€The new Bradykinesia Akinesia Incoordination (BRAIN) test: an online test of upper limb movement. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.69-e1.	1.9	0
726	119â€A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.70-e1.	1.9	0
727	Letters from Dom Pedro II to professor Brown-Séquard: imperial correspondence and neurophysiology. Arquivos De Neuro-Psiquiatria, 2012, 70, 633-636.	0.8	0
728	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2013, 28, 408-408.	3.9	0
729	The case of the locked house. Neurology, 2014, 83, 661-664.	1.1	0
730	Foreword. Parkinsonism and Related Disorders, 2016, 33, S1.	2.2	0
731	Reply: MRI findings of visual system alterations in Parkinson's disease. Brain, 2017, 140, e70-e70.	7.6	0
732	From Sgt. Pepper to Dreamachines: My Scientific Odyssey With William S. Burroughs. JAMA - Journal of the American Medical Association, 2017, 318, 2164.	7.4	0
733	2â€Movement disorders – the parkinson's névrose. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A1.2-A2.	1.9	0
734	Georges Simenon, Inspector Maigret and his relevance to the practice of Neurology. Arquivos De Neuro-Psiquiatria, 2017, 75, 189-191.	0.8	0
735	" Flâneur neurologique in paris―– A guide to pinpointing the houses of famous neurologists in the late XIX century. Journal of Clinical Neuroscience, 2018, 52, 32-36.	1.5	0
736	Sir William Osler's â€~Influences' for the Successful Physician, A Reappraisal After 126ÂYears. Archives of Medical Research, 2018, 49, 418-420.	3.3	0
737	Small spiral, big mass. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1189-1190.	1.9	0
738	Will the Real James Parkinson Please Stand Up? Another Fake James Parkinson. Movement Disorders Clinical Practice, 2019, 6, 269-270.	1.5	0

#	Article	IF	CITATIONS
739	La Folie des Grandeurs. Brain, 2020, 143, 2325-2328.	7.6	0
740	Senior moments. Brain, 2021, 144, 2892-2895.	7.6	0
741	Our Unforgettable Case of Malignant Motor Fluctuations in a Parkinson Patient. , 2012, , .		0
742	A Patient With Rapidly Progressive Dementia and Supranuclear Gaze Palsy: A Memorable Lesson on Prion Disorders. , 2012, , .		0
743	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. Arquivos De Neuro-Psiquiatria, 2021, , .	0.8	0
744	Dopamine devils. Arquivos De Neuro-Psiquiatria, 2021, 79, 941-942.	0.8	0
745	Le Bal des Folles. Brain, O, , .	7.6	О